Travere Therapeutics, Inc.

Travere Therapeutics, Inc.verified

TVTX

Price:

$6.16

Market Cap:

$468.95M

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in ...[Read more]

Industry

Biotechnology

IPO Date

2012-11-08

Stock Exchange

NASDAQ

Ticker

TVTX

The PE Ratio as of May 2024 (TTM) for Travere Therapeutics, Inc. (TVTX) is -1.14

According to Travere Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.14. This represents a change of -12.63% compared to the average of -1.30 of the last 4 quarters.

Travere Therapeutics, Inc. (TVTX) Historical PE Ratio (quarterly & annually)

How has TVTX PE Ratio performed in the past?

The mean historical PE Ratio of Travere Therapeutics, Inc. over the last ten years is -6.73. The current -1.14 PE Ratio has changed 1.59% with respect to the historical average. Over the past ten years (40 quarters), TVTX's PE Ratio was at its highest in in the March 2020 quarter at 194.67. The PE Ratio was at its lowest in in the December 2015 quarter at -70.82.

Quarterly (TTM)
Annual

Average

-6.73

Median

-6.82

Minimum

-14.62

Maximum

5.52

Travere Therapeutics, Inc. (TVTX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Travere Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 86.25%

Maximum Annual PE Ratio = 5.52

Minimum Annual Increase = -364.77%

Minimum Annual PE Ratio = -14.62

Quarterly (TTM)
Annual
YearPE RatioChange
2023-5.9924.48%
2022-4.81-53.31%
2021-10.3134.85%
2020-7.6586.25%
2019-4.11-53.91%
2018-8.91-34.85%
2017-13.68-6.46%
2016-14.62-364.77%
20155.52-299.85%
2014-2.76-5.92%

Travere Therapeutics, Inc. (TVTX) Average PE Ratio

How has TVTX PE Ratio performed in the past?

The current PE Ratio of Travere Therapeutics, Inc. (TVTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-7.04

5-year avg

-6.57

10-year avg

-6.73

Travere Therapeutics, Inc. (TVTX) PE Ratio vs. Peers

How is TVTX’s PE Ratio compared to its peers?

Travere Therapeutics, Inc.’s PE Ratio is greater than DICE Therapeutics, Inc. (-23.17), greater than Cytokinetics, Incorporated (-9.28), greater than Ventyx Biosciences, Inc. (-1.40), greater than Cogent Biosciences, Inc. (-3.67), greater than Nuvalent, Inc. (-29.96), greater than Cerevel Therapeutics Holdings, Inc. (-16.30), greater than Structure Therapeutics Inc. (-17.64), greater than Revolution Medicines, Inc. (-12.91), greater than Akero Therapeutics, Inc. (-6.06), greater than Avidity Biosciences, Inc. (-10.47), less than Protagonist Therapeutics, Inc. (11.42), greater than Stoke Therapeutics, Inc. (-6.14), greater than IDEAYA Biosciences, Inc. (-21.97), greater than AnaptysBio, Inc. (-3.92), greater than MeiraGTx Holdings plc (-4.57), greater than Keros Therapeutics, Inc. (-8.91), less than Homology Medicines, Inc. (-0.01), greater than Legend Biotech Corporation (-16.18), greater than Vaxcyte, Inc. (-17.58), greater than Apellis Pharmaceuticals, Inc. (-11.97),

Build a custom stock screener for Travere Therapeutics, Inc. (TVTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Travere Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Travere Therapeutics, Inc. (TVTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Travere Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Travere Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Travere Therapeutics, Inc. (TVTX)?

What is the highest PE Ratio for Travere Therapeutics, Inc. (TVTX)?

What is the 3-year average PE Ratio for Travere Therapeutics, Inc. (TVTX)?

What is the 5-year average PE Ratio for Travere Therapeutics, Inc. (TVTX)?

How does the current PE Ratio for Travere Therapeutics, Inc. (TVTX) compare to its historical average?